Findings Published From PRESTIGE Registry Evaluating High Platelet Reactivity


December 21, 2017—Results from the PRESTIGE registry were published by Thea C. Godschalk, MSc, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2017;10:2548–2556). PRESTIGE investigated high platelet reactivity (HPR) in patients presenting with ST-segment elevation myocardial infarction (STEMI) caused by stent thrombosis undergoing immediate percutaneous coronary intervention (PCI).

The background of the study is that HPR on P2Y12 inhibitors (HPR-ADP) is frequently observed in stable patients who have experienced stent thrombosis, but that the HPR rates in patients presenting with stent thrombosis for immediate PCI are unknown.

As summarized in JACC: Cardiovascular Interventions, the multicenter PRESTIGE registry included consecutive patients presenting with definite stent thrombosis. Platelet reactivity was measured with the VerifyNow P2Y12 or Aspirin assay (Accriva Diagnostics, representing ITC and Accumetrics) in 129 stent thrombosis patients presenting with STEMI before undergoing immediate PCI.

The investigators reported that HPR-ADP was observed in 76% of the patients, and HPR on aspirin (HPR-AA) was observed in 13% of the patients. HPR rates were similar in patients who were on maintenance P2Y12 inhibitors or aspirin since stent placement versus those without these medications. In addition, HPR-ADP was similar in patients loaded with a P2Y12 inhibitor shortly before immediate PCI versus those who were not. In contrast, HPR-AA trended to be lower in patients loaded with aspirin as compared with those not loaded.

The investigators concluded that approximately three of four stent thrombosis patients with STEMI undergoing immediate PCI had HPR-ADP, and 13% had HPR-AA. HPR rates were not influenced by whether patients were on maintenance antiplatelet therapy while developing stent thrombosis or loaded with P2Y12 inhibitors shortly before undergoing immediate PCI. These findings raise concerns that the majority of patients with stent thrombosis have suboptimal platelet inhibition undergoing immediate PCI, advised the investigators in JACC: Cardiovascular Interventions.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.